Contraceptives Market to 2018 – Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen

Publisher Name :
Date:9-Nov-2012
No. of pages: 85

GBI Research, a leading business intelligence provider, has released its latest research, “Contraceptives Market to 2018 Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen”, which provides insights into the global contraceptives market and market forecasts until 2018. The report provides an in-depth analysis of the most commonly used contraceptives, such as oral, topical, and injectable contraceptives, and devices such as intrauterine devices, condoms, and vaginal rings. The report also examines the usage patterns and annual cost of usage for these segments. It also includes insights into the contraceptives R&D product pipeline and explores the competitive landscape, including major companies in the contraceptives market. Finally, the report also includes analysis of the mergers and acquisitions (M&A) and licensing agreements that have taken place in the global contraceptives market.

The contraceptives market is growing, and more than 90 million people from seven major markets used them in 2011, with more than 24 million people having used them in the US alone. The user population is expected to grow gradually during the forecast period and reach more than 94 million in 2018.

According to GBI Research’s analysis, in 2011, the contraceptives market was worth $10.2 billion, indicating a Compounded Annual Growth Rate (CAGR) of 2.7% between 2004 and 2011. By 2018, the market is expected to reach $11.8 billion, growing at a CAGR of 2.1%. The launch of the FC patch, AG200-15, Savvy Gel, LNG 20, Pill-Plus and some key products in the late stage pipeline combined with increasing awareness are expected to drive the market.

The annual cost of usage for contraceptives was $113 in 2011, which grew from $104 in 2004 at a CAGR of 1.2%. This is expected to grow to $125 in 2018, at a CAGR of 1.4% between 2011 and 2018. The growth rate can be attributed to factors such as the expected patent expiry of Mirena and Yaz. In the forecast period, CSD500, a condom manufactured by Futura Medical and licensed to Reckitt and Benckiser, is expected to strengthen the condom market.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

Scope

  • Data and analysis on the contraceptives market in leading geographies: the US, the UK, Germany, France, Italy, Spain and Japan; along with their reach in emerging markets.
  • Annualized market data for oral contraceptives, topical contraceptives, injectable contraceptives, condoms, intrauterine devices and vaginal rings in the contraceptives market from 2004-2011, with forecasts to 2018.
  • Market data on the therapeutic landscape, which covers oral, topical and injectable contraceptives, and includes market revenues, treatment usage patterns and the annual cost of usage.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the contraceptives market, which includes companies such as Bayer, Merck, Church & Dwight, Warner Chilcott Company, and Pfizer.
  • Key M&A activities and licensing agreements that took place from 2008-2012 in the contraceptives market.

Reasons to buy

  • Align your product portfolio to markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Devise a more specifically-tailored country strategy through understanding of the key drivers and barriers in the contraceptives market of all the major countries.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Contraceptives Market to 2018 – Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 9

2 Contraceptives Market to 2018 - Introduction 10

3 Contraceptives Market to 2018 - Market Overview 12
3.1 Introduction 12
3.2 Revenue Forecasts for Contraceptives Market 12
3.2.1 Revenues 12
3.2.2 Annual Cost of Usage for Contraceptives 15
3.2.3 Contraceptive Users 16
3.3 Drivers and Barriers for the Contraceptives Market 17
3.3.1 Drivers for Contraceptives Therapeutics Market 17
3.3.2 Barriers for Contraceptives 18

4 Contraceptives Market to 2018 - Geographical Landscape 19
4.1 The US 19
4.1.1 Revenue 19
4.1.2 Annual Cost of Usage for Contraceptives 20
4.1.3 Contraceptive Users 21
4.2 Top Five Countries of Europe 22
4.2.1 Revenue 22
4.2.2 Annual Cost of Usage for Contraceptives 23
4.2.3 Contraceptive Users 24
4.3 Japan 25
4.3.1 Revenue 25
4.3.2 Annual Cost of Usage for Contraceptives 26
4.3.3 Contraceptive Users 27

5 Contraceptives Market to 2018 - Therapeutic Landscape 28
5.1 Oral Contraceptives 28
5.1.1 Introduction 28
5.1.2 Combined Hormonal Contraception 29
5.1.3 Oral Contraceptive Historic Trends 29
5.1.4 Recently Approved Combined Oral Contraceptives 29
5.1.5 Revenue 30
5.1.6 Annual Cost of Usage 33
5.1.7 Oral Contraceptive Users 34
5.2 Injectables 35
5.2.1 Introduction 35
5.2.2 Revenue 35
5.2.3 Annual Cost of Usage 39
5.2.4 Injectable Contraceptive Users 40
5.3 Topical Contraceptives 41
5.3.1 Introduction 41
5.3.2 Revenue 42
5.3.3 Annual Cost of Usage 45
5.3.4 Topical Contraceptive Users 46

6 Contraceptives Market to 2018 - Devices Landscape 47
6.1 Vaginal Ring 47
6.1.1 Introduction 47
6.1.2 Revenue 47
6.1.3 Geographical Segmentation 49
6.1.4 Annual Cost of Usage 51
6.1.5 Vaginal Ring Users 52
6.2 Intrauterine Device 53
6.2.1 Introduction 53
6.2.2 Revenue 53
6.2.3 Geographical Segmentation 55
6.2.4 Annual Cost of Usage 57
6.2.5 IUDs Users 58
6.3 Condoms 59
6.3.1 Introduction 59
6.3.2 Revenue 59
6.3.3 Geographical Segmentation 60
6.3.4 Annual Cost of Usage 62
6.3.5 Condom Users 63

7 Emerging Markets 64
7.1 China 64
7.2 Australia 65
7.3 India 66

8 Contraceptives Market to 2018 - Pipeline Analysis 67
8.1 Introduction 67
8.2 Profiles of Promising Drugs in the Global Contraceptives Market 68
8.2.1 AG200-15 68
8.2.2 FC Patch Low 68
8.2.3 Pill-Plus 69

9 Contraceptives Market to 2018 - Competitive Landscape 70
9.1 Market Share Analysis - Contraceptives Market 70
9.2 Drug Profile of Major Marketed Contraceptives 71
9.2.1 Yaz/Yasmin 71
9.2.2 Mirena 71
9.2.3 Nuvaring 71
9.3 Competitive Profiling 72
9.3.1 Bayer 72
9.3.2 Merck 73
9.3.3 Church & Dwight 74
9.3.4 Warner Chilcott Company, Inc. 75
9.3.5 Pfizer Inc. 76

10 Contraceptives Market to 2018 - Strategic Consolidations 77
10.1 Mergers and Acquisitions 77
10.1.1 Major M&A Deals 77
10.1.2 Licensing Agreements 77
10.1.3 Deals by Geography 78
10.1.4 Major Licensing Agreements 78
10.1.5 Co-development 79

11 Contraceptives Market to 2018 - Appendix 80
11.1 Market Definitions 80
11.2 Abbreviations 80
11.3 Bibliography 80
11.4 Research Methodology 81
11.4.1 Coverage 82
11.4.2 Secondary Research 82
11.4.3 Primary Research 82
11.4.4 Expert Panel Validation 83
11.5 Therapeutic Landscape 83
11.5.1 Epidemiology-Based Forecasting 83
11.5.2 Market Size by Geography 84
11.6 Geographical Landscape 84
11.7 Pipeline Analysis 84
11.8 Competitive Landscape 84
11.9 Contact Us 85
11.10 Disclaimer 85

List of Tables

Table 1: Contraceptives Market, Global, Revenue ($bn), 2004-2011 12
Table 2: Contraceptives Market, Global, Revenue Forecasts ($bn), 2011-2018 12
Table 3: Contraceptives Market, Global, Revenue by Geographical Segmentation ($m), 2004-2011 13
Table 4: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 14
Table 5: Contraceptives Market, Global, Annual Cost of Usage ($), 2004-2011 15
Table 6: Contraceptives Market, Global, Annual Cost of Usage ($), 2011-2018 15
Table 7: Contraceptives Market, Global, Contraceptive Users (Million), 2004-2011 16
Table 8: Contraceptives Market, Global, Contraceptive Users (Million), 2011-2018 16
Table 9: Contraceptives Market, The US, Revenue ($bn), 2004-2011 19
Table 10: Contraceptives Market, The US, Revenue Forecasts ($bn), 2011-2018 19
Table 11: Contraceptives Market, The US, Annual Cost of Usage ($), 2004-2011 20
Table 12: Contraceptives Market, The US, Annual Cost of Usage ($), 2011-2018 20
Table 13: Contraceptives Market, The US, Contraceptive Users (Million), 2004-2011 21
Table 14: Contraceptives Market, The US, Contraceptive Users (Million), 2011-2018 21
Table 15: Contraceptives Market, Top Five Countries of Europe, Revenue ($m), 2004-2011 22
Table 16: Contraceptives Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018 22
Table 17: Contraceptives Market, Top Five Countries of Europe, Annual Cost of Usage ($), 2004-2011 23
Table 18: Contraceptives Market, Top Five Countries of Europe, Annual Cost of Usage ($), 2011-2018 23
Table 19: Contraceptives Market, Top Five Countries of Europe, Contraceptive Users (Million), 2004-2011 24
Table 20: Contraceptives Market, Top Five Countries of Europe, Contraceptive Users (Million), 2011-2018 24
Table 21: Contraceptives Market, Japan, Revenue ($m), 2004-2011 25
Table 22: Contraceptives Market, Japan, Revenue Forecasts ($m), 2011-2018 25
Table 23: Contraceptives Market, Japan, Annual Cost of Usage ($), 2004-2011 26
Table 24: Contraceptives Market, Japan, Annual Cost of Usage ($), 2011-2018 26
Table 25: Contraceptives Market, Japan, Contraceptive Users (Million), 2004-2011 27
Table 26: Contraceptives Market, Japan, Contraceptive Users (Million), 2011-2018 27
Table 27: Oral Contraceptives Market, Global, Revenue ($bn), 2004-2011 30
Table 28: Oral Contraceptives Market, Global, Revenue Forecasts ($bn), 2011-2018 30
Table 29: Oral Contraceptives Market, Global, Revenue by Geographical Segmentation ($m), 2004-2011 31
Table 30: Oral Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 32
Table 31: Oral Contraceptives Market, Global, Annual Cost of Usage ($), 2004-2011 33
Table 32: Oral Contraceptives Market, Global, Annual Cost of Usage ($), 2011-2018 33
Table 33: Oral Contraceptives Market, Global, Users (Million), 2004-2011 34
Table 34: Oral Contraceptives Market, Global, Users (Million), 2011-2018 34
Table 35: Injectables Market, Global, Revenue ($m), 2004-2011 36
Table 36: Injectables Market, Global, Revenue Forecasts ($m), 2011-2018 36
Table 37: Injectables Market, Global, Revenue by Geographical Segmentation ($m), 2004-2011 37
Table 38: Injectables Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 38
Table 39: Injectables Market, Global, Annual Cost of Usage ($), 2004-2011 39
Table 40: Injectables Market, Global, Annual Cost of Usage ($), 2011-2018 39
Table 41: Injectable Contraceptives Market, Global, Users (‘000), 2004-2011 40
Table 42: Injectable Contraceptives Market, Global, Users (‘000), 2011-2018 40
Table 43: Topical Contraceptives Market, Global, Revenue ($m), 2004-2011 42
Table 44: Topical Contraceptives Market, Global, Revenue Forecasts ($m), 2011-2018 42
Table 45: Topical Contraceptives Market, Global, Revenue by Geographical Segmentation ($m), 2004-2011 43
Table 46: Topical Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 44
Table 47: Topical Contraceptives Market, Global, Annual Cost of Usage ($), 2004-2011 45
Table 48: Topical Contraceptives Market, Global, Annual Cost of Usage ($), 2011-2018 45
Table 49: Topical Contraceptives Market, Global, Users (Million), 2004-2011 46
Table 50: Topical Contraceptives Market, Global, Users (Million), 2011-2018 46
Table 51: Vaginal Ring Market, Global, Revenue ($m), 2004-2011 48
Table 52: Vaginal Ring Market, Global, Revenue Forecasts ($m), 2011-2018 48
Table 53: Vaginal Ring Market, Global, Revenue by Geographical Segmentation ($m), 2004-2011 49
Table 54: Vaginal Ring Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 50
Table 55: Vaginal Ring Market, Global, Annual Cost of Usage ($), 2004-2011 51
Table 56: Vaginal Ring Market, Global, Annual Cost of Usage ($), 2011-2018 51
Table 57: Vaginal Ring Market, Global, Users ('000), 2004-2011 52
Table 58: Vaginal Ring Market, Global, Users (‘000), 2011-2018 52
Table 59: Intrauterine Devices Market, Global, Revenue ($m), 2004-2011 54
Table 60: Intrauterine Device Market, Global, Revenue Forecasts ($m), 2011-2018 54
Table 61: IUDs Market, Global, Revenue by Geographical Segmentation ($m), 2004-2011 55
Table 62: IUDs Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 56
Table 63: IUDs Market, Global, Annual Cost of Usage ($), 2004-2011 57
Table 64: IUDs Market, Global, Annual Cost of Usage ($), 2011-2018 57
Table 65: IUDs Market, Global, Users (Million), 2004-2011 58
Table 66: IUDs Market, Global, Users (Million), 2011-2018 58
Table 67: Condoms Market, Global, Revenue ($bn), 2004-2011 59
Table 68: Condoms Market, Global, Revenue Forecasts ($bn), 2011-2018 59
Table 69: Condoms Market, Global, Revenue by Geographical Segmentation ($m), 2004-2011 60
Table 70: Condoms Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 61
Table 71: Condoms Market, Global, Annual Cost of Usage ($), 2004-2011 62
Table 72: Condoms Market, Global, Annual Cost of Usage ($), 2011-2018 62
Table 73: Condom Market, Global, Users (Million), 2004-2011 63
Table 74: Condom Market, Global, Users (Million), 2011-2018 63
Table 75: Contraceptives Market, Method of Contraceptive Used (%), China 64
Table 76: Contraceptives Market, Method of Contraceptive Used (%), Australia 65
Table 77: Contraceptives Market, Method of Contraceptive Usage (%), India 66
Table 78: Contraceptives Market, Global, Product Pipeline by Phase, 2012 67
Table 79: Contraceptives Market, Global, Revenues of Major Marketed Contraceptives ($m), 2011 71

List of Figures

Figure 1: Contraceptives Market, Global, Revenue Forecasts ($bn), 2004-2018 12
Figure 2: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2004-2018 13
Figure 3: Contraceptives Market, Global, Annual Cost of Usage ($), 2004-2018 15
Figure 4: Contraceptives Market, Global, Contraceptive Users (Million), 2004-2018 16
Figure 5: Contraceptives Market, Global, Drivers and Barriers, 2011 17
Figure 6: Contraceptives Market, The US, Revenue Forecasts ($bn), 2004-2018 19
Figure 7: Contraceptives Market, The US, Annual Cost of Usage ($), 2004-2018 20
Figure 8: Contraceptives Market, The US, Contraceptive Users (Million), 2004-2018 21
Figure 9: Contraceptives Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2004-2018 22
Figure 10: Contraceptives Market, Top Five Countries of Europe, Annual Cost of Usage ($), 2004-2018 23
Figure 11: Contraceptives Market, Top Five Countries of Europe, Contraceptive Users (Million), 2004-2018 24
Figure 12: Contraceptives Market, Japan, Revenue Forecasts ($m), 2004-2018 25
Figure 13: Contraceptives Market, Japan, Annual Cost of Usage ($), 2004-2018 26
Figure 14: Contraceptives Market, Japan, Contraceptive Users (Million), 2004-2018 27
Figure 15: Oral Contraceptives Market, Global, Revenue Forecasts ($bn), 2004-2018 30
Figure 16: Oral Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2004-2018 31
Figure 17: Oral Contraceptives Market, Global, Annual Cost of Usage ($), 2004-2018 33
Figure 18: Oral Contraceptives Market, Global, Users (Million), 2004-2018 34
Figure 19: Injectables Market, Global, Revenue Forecasts ($m), 2004-2018 35
Figure 20: Injectables Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2004-2018 37
Figure 21: Injectables Market, Global, Annual Cost of Usage ($), 2004-2018 39
Figure 22: Injectable Contraceptives Market, Global, Users (‘000), 2004-2018 40
Figure 23: Topical Contraceptives Market, Global, Revenue Forecasts ($m), 2004-2018 42
Figure 24: Topical Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2004-2018 43
Figure 25: Topical Contraceptives Market, Global, Annual Cost of Usage ($), 2004-2018 45
Figure 26: Topical Contraceptives Market, Global, Users (Million), 2004-2018 46
Figure 27: Vaginal Ring Market, Global, Revenue Forecasts ($m), 2004-2018 47
Figure 28: Vaginal Ring Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2004-2018 49
Figure 29: Vaginal Ring Market, Global, Annual Cost of Usage ($), 2004-2018 51
Figure 30: Vaginal Ring Market, Global, Users (‘000), 2004-2018 52
Figure 31: Intrauterine Devices Market, Global, Revenue Forecasts ($m), 2004-2018 53
Figure 32: IUDs Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2004-2018 55
Figure 33: IUDs Market, Global, Annual Cost of Usage ($), 2004-2018 57
Figure 34: IUDs Market, Global, Users (Million), 2004-2018 58
Figure 35: Condoms Market, Global, Revenue Forecasts ($bn), 2004-2018 59
Figure 36: Condoms Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2004-2018 60
Figure 37: Condoms Market, Global, Annual Cost of Usage ($), 2004-2018 62
Figure 38: Condom Market, Global, Users (Million), 2004-2018 63
Figure 39: Contraceptives Market, Global, Product Pipeline by Phase, (%), 2011 67
Figure 40: Contraceptives Market, Global, Market Share Analysis, (%), 2011 70
Figure 41: Contraceptives Market, Global, Bayer, SWOT Analysis, 2011 72
Figure 42: Contraceptives Market, Global, Merck, SWOT Analysis, 2011 73
Figure 43: Contraceptives Market, Global, Church & Dwight, SWOT Analysis, 2011 74
Figure 44: Contraceptives Market, Global, Warner Chilcott Company, Inc., SWOT Analysis, 2011 75
Figure 45: Contraceptives Market, Global, Pfizer Inc., SWOT Analysis, 2011 76
Figure 46: Contraceptives Market, Global, Licensing Agreements by Geography, 2011 78

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Chronic Lymphocytic Leukemia (CLL) Treatment Market worth $3.3 billion by 2018
  • New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, says GlobalData. The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to …

  • Global Biosimilars Market to Grow at a CAGR of 8.3%, to reach $262 billion by 2019
  • Lucrative Biosimilars Space to Erode Biologics Market from 2019, says GlobalData The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking …

  • Saudi Pharmaceutical Market worth $5.9 billion by 2020
  • A high burden of chronic diseases, improving regulatory guidelines and the launch of new products will provide the necessary impetus for the growth of the pharmaceutical market in Saudi Arabia The Saudi pharmaceutical market is one of the largest markets …

  • Malaysia Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 145
    BMI View: We remain generally optimistic towards Malaysia's commitment to provide better quality and access to healthcare, as the government plans to expand and upgrade its hospital network. However, we have downgraded Malaysia's pharmaceutical sales forecast due to a slowdown in pharmaceutical trade in 2013. The country's slower economic growth in 2014, coupled with the fact that investment in the pharmaceuticals sector will take longer than expected to bring returns, are downside risks to our ......
  • Portugal Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 116
    BMI View: Faster-than-expected economic growth last quarter has led us to revise our healthcare and pharmaceutical forecasts slightly upwards. As forecast previously, BMI expects Portugal's healthcare market to return to growth in 2015, while pharmaceuticals will not return to growth until 2019. This is because while Portugal exited its bailout programme in May 2014 without the need for a new financial package, government austerity measures are likely to curb pharmaceutical reimbursement. Portug......
  • Qatar Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 106
    BMI View: Medicine prices are expected to decline shortly in Qatar amid the 'imminent' unification of medicine importation channels and the adoption of a new medicine pricing mechanism by the member countries of the Gulf Co-operation Council (GCC). The unified regional pharmaceutical pricing policy among GCC member states will reduce medicine prices in Qatar and improve its national drug accessibility, if implemented properly. Although the drug pricing controls can potentially negatively affect ......
  • South Africa Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 125
    BMI View: South Africa is the best investment opportunity for multinational drugmakers seeking to enter the African market - boasting the largest medicines market on the continent and poised for high single-digit growth over the next decade. Headline Expenditure Projections ? Pharmaceuticals: ZAR34.01bn (USD3.52bn) in 2013 to ZAR37.53bn (USD3.51bn) in 2014; +10.3% in local currency terms and -0.5% in US dollar terms. Forecast broadly in line with Q114. ? Healthcare: ZAR301.49bn (USD31.24bn) in 2......
  • Sri Lanka Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 80
    BMI View: Sri Lanka's pharmaceutical sector has received investment from domestic and foreign - notably Indian - investors in recent years, as economic growth has picked up and the government focused on improving the domestic pharmaceutical sector. We therefore expect that pharmaceutical and healthcare sector growth will outpace economic growth over the five-year forecast period. Improved relations with India, after the country abstained from voting on the UNHCR resolution, are likely to spur fu......
  • United Arab Emirates Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 126
    BMI View: The UAE is one of the more developed markets in the Middle East and has a strong existing healthcare infrastructure. As the UAE is aiming to introduce comprehensive health insurance throughout the country, allowing businesses to shoulder much of the cost of this expanded coverage, the government will gradually contribute less to the country's healthcare spending. Between 2013 and 2018, we expect private sector healthcare spending to outpace public. However, the public sector will remai......
  • Czech Republic Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 112
    BMI View: Pharmaceutical sales will decline further this year, following the release of poor sales data from the first quarter. Price declines throughout Europe and restructuring of the healthcare system will continue to impact demand within the Czech Republic. We also believe the new centre-left coalition government poses downside risk to our forecasts given its commitment to containing healthcare costs and improving access to medicines. Despite these concerns, our view is more optimistic over ......
  • Denmark Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 58
    BMI View: Like many other Western European countries, Denmark's expanding elderly population will ensure that demand for quality healthcare remains high and will be a key driving factor for its wellestablished, albeit relatively small, pharmaceutical market. The robust demand for healthcare services will see the Danish government continue to adapt strategies and cost-containment measures to manage increasing healthcare costs. Despite this, we believe the country's high per-capita drug expenditur......
  • Iraq Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 83
    BMI View: Thanks to the government's expansionary fiscal policy, spending on education, health and public services will increase. The Iraqi government has reportedly pledged to invest USD12bn into healthcare expansions in 2014, and the Ministry of Health recently awarded 18 health project contracts worth USD276mn. In addition, new restrictions aim to end the chaos in which materials have entered the country in previous years, targeting control over drug policy and ensuring the supply of medicine......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs